ALN-HBV-02

Generic Name: ALN-HBV-02

Advanced Drug Monograph

Access comprehensive pharmacological analysis, clinical applications, and therapeutic considerations.

Clinical Trials

A Study to Evaluate Tobevibart + Elebsiran in Chronic HDV Infection

Phase 3

Recruiting

Conditions: Viral Hepatitis

Interventions: Drug: Tobevibart
Drug: Elebsiran

First Posted Date: 2025-03-30

Last Posted Date: 2025-05-20

Lead Sponsor: Vir Biotechnology, Inc.

Target Recruit Count: 120

Registration Number: NCT06903338

Locations: 🇲🇩
Investigative Site, Chisinau, Moldova, Republic of

Dose-Escalation Prime/Boost Therapeutic Vaccination Study Of 2 Chimp Adenoviral Vectors in Adults With Chronic HBV On Nucleos(t)Ide Therapy

Phase 1

Recruiting

Conditions: Chronic Hepatitis B

Interventions: Biological: VRON-0200-AdC6
Drug: VIR-2218
Biological: VRON-0200-AdC7
Drug: VIR-3434

First Posted Date: 2023-10-06

Last Posted Date: 2024-11-15

Lead Sponsor: Virion Therapeutics

Target Recruit Count: 48

Registration Number: NCT06070051

Locations: 🇳🇿
Aotearoa Clinical Trials, Middlemore Hospital, Auckland, New Zealand
🇭🇰
Chinese University of Hong Kong, Hong Kong, Hong Kong
🇳🇿
Auckland City Hospital, Auckland, New Zealand

Investigate the Efficacy and Safety of BRII-835 (VIR-2218) and PEG-IFNα Combination Therapy in Chronic HBV Patients

Phase 2

Active, not recruiting

Conditions: Chronic Hepatitis B Virus Infection

Interventions: Biological: PEG-IFNα
Drug: BRII-835

First Posted Date: 2023-08-01

Last Posted Date: 2024-03-21

Lead Sponsor: Brii Biosciences Limited

Target Recruit Count: 75

Registration Number: NCT05970289

Locations: 🇹🇭
nvestigative Site 66007, Chiang Mai, Thailand
🇦🇺
Investigative Site 61003, Melbourne, Victoria, Australia
🇦🇺
Investigative Site 61001, Kingswood, New South Wales, Australia

and more 25 locations

A Study to Investigate the Effect of Renal Impairment on the Pharmacokinetics and Safety of VIR-2218

Phase 1

Active, not recruiting

Conditions: Renal Impairment

Interventions: Drug: VIR-2218

First Posted Date: 2023-05-06

Last Posted Date: 2025-04-06

Lead Sponsor: Vir Biotechnology, Inc.

Target Recruit Count: 28

Registration Number: NCT05844228

Locations: 🇺🇸
Inland Empire Clinical Trials, Rialto, California, United States
🇺🇸
Floridian Clinical Research, Miami Lakes, Florida, United States
🇺🇸
Orlando Clinical Research Center, Orlando, Florida, United States

A Platform Study to Evaluate Investigational Therapies in Chronic Hepatitis B Infection

Phase 1

Active, not recruiting

Conditions: Hepatitis B, Chronic

Interventions: Drug: VIR-3434
Drug: TDF
Drug: VIR-2218
Drug: PEG-IFNα

First Posted Date: 2022-11-10

Last Posted Date: 2025-04-06

Lead Sponsor: Vir Biotechnology, Inc.

Target Recruit Count: 150

Registration Number: NCT05612581

Locations: 🇬🇧
Investigative Site, Manchester, United Kingdom

Effect of Hepatic Impairment on the Pharmacokinetics and Safety of VIR-2218 and VIR-3434

Phase 1

Recruiting

Conditions: Hepatic Impairment
Cirrhosis

Interventions: Drug: VIR-2218
Drug: VIR-3434

First Posted Date: 2022-08-02

Last Posted Date: 2024-05-03

Lead Sponsor: Vir Biotechnology, Inc.

Target Recruit Count: 144

Registration Number: NCT05484206

Locations: 🇺🇸
Inland Empire Clinical Trials, Rialto, California, United States
🇺🇸
Orange County Research Center, Tustin, California, United States
🇺🇸
Floridian Clinical Research, Miami Lakes, Florida, United States

and more 2 locations

SOLSTICE: Combination Therapy for the Treatment of Chronic Hepatitis D Infection.

Phase 2

Recruiting

Conditions: Hepatitis D, Chronic

Interventions: Drug: VIR-3434
Drug: NRTI
Drug: VIR-2218

First Posted Date: 2022-07-18

Last Posted Date: 2024-08-09

Lead Sponsor: Vir Biotechnology, Inc.

Target Recruit Count: 124

Registration Number: NCT05461170

Locations: 🇬🇧
Investigative Site, Manchester, United Kingdom

Study to Evaluate the Safety and Efficacy of Selgantolimod (SLGN)-Containing Combination Therapies for the Treatment of Chronic Hepatitis B (CHB)

Phase 2

Completed

Conditions: Chronic Hepatitis B

Interventions: Drug: Tenofovir Alafenamide
Drug: VIR-2218
Drug: Selgantolimod
Drug: Nivolumab

First Posted Date: 2021-05-18

Last Posted Date: 2024-09-30

Lead Sponsor: Gilead Sciences

Target Recruit Count: 103

Registration Number: NCT04891770

Locations: 🇩🇰
Aalborg University Hospital, Aalborg, Denmark
🇦🇺
Liverpool Hospital, Liverpool, New South Wales, Australia
🇩🇰
Odense University Hospital, Odense, Denmark

and more 23 locations